National Cancer Center, Japan   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (1961)

Organization Overview

First Clinical Trial
2004
NCT00292708
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Gastrointestinal Medical Oncology, National cancer center hospital | Deputy Director for Research of the National Cancer Centre | Japan National Cancer Center Hospital | Kohei Shitara | Masahiro Tsuboi | National Cancer Center Hospital | National Cancer Center Hospital East | National Cancer Center Hospital East, Japan | National Cancer Center Hospital Tokyo, Japan | National Cancer Center Hospital, Tokyo JAPAN | National Cancer Center, Japan | National Cancer Centre Hospital, Tokyo

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Squamous Cell (Phase 1)

Colorectal Neoplasms (Phase 3)

Enuresis (Phase 2)

Esophageal Neoplasms (Phase 1)

Esophageal Squamous Cell Carcinoma (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Incontinence (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 30